Agilent

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agilent and other ETFs, options, and stocks.

About A

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. 

CEO
Padraig Mcdonnell
CEOPadraig Mcdonnell
Employees
18,100
Employees18,100
Headquarters
Santa Clara, California
HeadquartersSanta Clara, California
Founded
1999
Founded1999
Employees
18,100
Employees18,100

A Key Statistics

Market cap
39.12B
Market cap39.12B
Price-Earnings ratio
30.25
Price-Earnings ratio30.25
Dividend yield
0.72%
Dividend yield0.72%
Average volume
2.13M
Average volume2.13M
High today
$138.57
High today$138.57
Low today
$137.81
Low today$137.81
Open price
$138.46
Open price$138.46
Volume
498.23K
Volume498.23K
52 Week high
$160.27
52 Week high$160.27
52 Week low
$96.43
52 Week low$96.43

Stock Snapshot

The current Agilent(A) stock price is $138.32, with a market capitalization of 39.12B. The stock trades at a price-to-earnings (P/E) ratio of 30.25 and offers a dividend yield of 71.7%.

As of 2025-12-25, Agilent(A) stock has fluctuated between $137.81 and $138.57. The current price stands at $138.32, placing the stock +0.4% above today's low and -0.2% off the high.

Agilent(A) shares are trading with a volume of 498.23K, against a daily average of 2.13M.

In the last year, Agilent(A) shares hit a 52-week high of $160.27 and a 52-week low of $96.43.

In the last year, Agilent(A) shares hit a 52-week high of $160.27 and a 52-week low of $96.43.

A News

Simply Wall St 3d
Will Agilent’s Native-Read Sequencing Push with Wasatch BioLabs Redefine Its Genomics Narrative?

In December 2025, Wasatch BioLabs announced a co-marketing agreement with Agilent Technologies to pair Agilent’s SureSelect and Avida enrichment chemistries wit...

Will Agilent’s Native-Read Sequencing Push with Wasatch BioLabs Redefine Its Genomics Narrative?

Analyst ratings

67%

of 21 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

People also own

Based on the portfolios of people who own A. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.